Results 71 to 80 of about 4,368 (201)
Finerenone: a new mineralocorticoid receptor antagonist to beat chronic kidney disease
, 2022 Purpose of review: Clinical trials of the mineralocorticoid receptor antagonist (MRA) finerenone published recently suggest that they improve outcomes in patients with diabetic kidney disease (DKD).
Rajesh Raj (14747452)
core
Metabolic Memory in Cardiovascular Disease: Encoding, Propagation, and Therapeutic Targeting
Advanced Science, Volume 13, Issue 54, 28 September 2026.Cardiovascular risk often persists after metabolic abnormalities are corrected. This conceptual Review frames such persistence as metabolic memory, encoded through a narrowing therapeutic window from reversible marks to irreversible damage, with continuous input from peripheral organs.
Cheng Cheng +12 more
wiley +1 more source
Cochrane Evidence Synthesis and Methods, Volume 4, Issue 5, September 2026.ABSTRACT Introduction Artificial intelligence (AI) is a branch of technology enabling machines to emulate complex human skills; it can also entail problem‐solving using bioinspired methods. It is used for automating systematic literature reviews (SLR), that is, defining a clinical question, locating relevant literature, preliminary screening, study ...
Ana M. Barragán +5 more
wiley +1 more source
The role of finerenone in heart failure
Trends in Cardiovascular MedicineHeart failure (HF) with mildly reduced or preserved ejection fraction (HFmrEF/HFpEF) represents approximately half of all HF cases, yet therapeutic options are limited. Mineralocorticoid receptor (MR) overactivation by aldosterone has long been recognized as a key driver of vascular inflammation, cardiac fibrosis, and cardiac hypertrophy ...
Hassan Ismahel, Kieran F. Docherty
openaire +2 more sources
Journal of Market Access & Health PolicyThis study aimed to close an evidence gap concerning the relative efficacy of finerenone versus SGLT2is in patients with chronic kidney disease (CKD) and type 2 diabetes (T2D). Canagliflozin was selected as a proxy for the SGLT2i class.
David Cherney +6 more
doaj +1 more source
Metabolic Syndrome: From Mechanisms to Therapeutic Interventions
MedComm, Volume 7, Issue 9, September 2026.A comprehensive overview of molecular mechanisms delves into the potential disease mechanisms of metabolic syndrome, including complex mechanisms such as insulin resistance, chronic low‐grade inflammation, oxidative stress, and epigenetic modifications, and how these mechanisms contribute to the development of metabolic syndrome. Here, the relationship
Mengyao Yan, Qian Xiang
wiley +1 more source
A FIDELITY Analysis on Finerenone With SGLT-2i and GLP-1RA in CKD
Kidney International ReportsIntroduction: Finerenone demonstrated kidney and cardiovascular benefits in participants with chronic kidney disease (CKD) and type 2 diabetes (T2D) on optimized renin-angiotensin system (RAS) inhibition in FIDELITY, a pooled individual-level analysis of
Ajay K. Singh +10 more
doaj +1 more source
Real-world outcomes of Finerenone in Primary Aldosteronism
Primary aldosteronism (PA) treatment with mineralocorticoid receptor antagonists (MRAs) is effective but limited by side-effects and low potency of currently available options.
Uslar, Thomas +4 more
core +1 more source
Kidney Protection, Obesity Treatment, and Multiorgan Biology: When More Therapy Is—And Is Not—Better
Journal of Diabetes, Volume 18, Issue 10, October 2026.
Zachary T. Bloomgarden +1 more
wiley +1 more source